GO:0046839 phospholipid dephosphorylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046839 (phospholipid dephosphorylation) is the biological process of removing one or more phosphate groups from a phosphorylated lipid, as defined by QuickGO.
• This process is central to phosphoinositide turnover and controls membrane identity, signaling, and trafficking.
• Key enzymes include lipid phosphate phosphatases (LPPs) and SHIP2 (INPPL1), which dephosphorylate phosphatidic acid and phosphatidylinositol (3,4,5)-trisphosphate, respectively.
• Dysregulation of phospholipid dephosphorylation is linked to cancer, opsismodysplasia, and immune signaling disorders.
• Bacterial pathogens can exploit host phospholipid dephosphatases to evade pyroptosis, highlighting its role in infection.
• CRISPR knockout, point-mutation, and knock-in models are essential to dissect the causal roles of phosphatases such as INPPL1 and LPPs in disease.
Description
Phospholipid dephosphorylation (GO:0046839) is a fundamental biological process that removes phosphate groups from phosphorylated lipids, thereby modulating the charge, shape, and signaling capacity of membrane lipids. This process is essential for maintaining the asymmetric distribution of phospholipids and for the dynamic interconversion of phosphoinositides, which act as molecular switches in signal transduction, membrane trafficking, and cell survival. Researchers study phospholipid dephosphorylation to understand how cells decode lipid signals and how their dysregulation contributes to diseases ranging from cancer to skeletal disorders. The reaction is catalyzed by a diverse set of phosphatases, including lipid phosphate phosphatases (LPPs) and the SH2-domain-containing inositol 5-phosphatase SHIP2 (encoded by INPPL1), which target distinct lipid substrates and are subject to tight spatial and temporal regulation. Because lipid phosphate levels influence processes as varied as endocytosis, immunological synapse formation, and host-pathogen interactions, phospholipid dephosphorylation sits at the crossroads of cell biology and disease.
phospholipid dephosphorylation At A Glance
| GO ID | GO:0046839 |
|---|---|
| GO term | phospholipid dephosphorylation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Removal of phosphate groups from phosphorylated lipids, regulating lipid signaling and membrane dynamics |
| Key enzymes | Lipid phosphate phosphatases (LPPs), SHIP2 (INPPL1), and other lipid phosphatases |
| Substrates | Phosphatidic acid, phosphatidylinositol (3,4,5)-trisphosphate, and other phosphorylated lipids |
| Cellular processes | Endocytosis, immunological synapse formation, pyroptosis inhibition |
| Disease relevance | Cancer, opsismodysplasia, immune disorders |
What Is GO:0046839?
Phospholipid dephosphorylation is the biochemical process that removes one or more phosphate groups from a phosphorylated lipid molecule. Lipids are substances soluble in organic solvents but only sparingly soluble in water, and their phosphorylation state often determines their biological activity and localization. This process is mediated by specific enzymes called lipid phosphatases, which hydrolyze phosphate ester bonds on substrates such as phosphatidic acid, phosphatidylinositol phosphates, and other phosphorylated lipids. By reversing the action of lipid kinases, phospholipid dephosphorylation helps set the steady-state levels of signaling lipids and is therefore a key node in cellular signal transduction and membrane dynamics.
Why Is phospholipid dephosphorylation Important in Cell Biology?
Phospholipid dephosphorylation is critically important because it controls the abundance and localization of bioactive lipids that orchestrate cell signaling, membrane trafficking, and immune responses. For example, the dephosphorylation of phosphatidylinositol (3,4,5)-trisphosphate by SHIP2 terminates PI3K signaling, thereby influencing cell proliferation and survival. In the immune system, lipid switches at the immunological synapse depend on phospholipid dephosphorylation to fine-tune T-cell activation. Moreover, pathogens can hijack host phosphatases to suppress inflammatory cell death, underscoring the process as a battleground in infection. Consequently, mutations or altered expression of lipid phosphatases are associated with human diseases such as cancer and opsismodysplasia, making this process a prime target for therapeutic intervention and a rich area for CRISPR-based functional studies.
• Regulates phosphoinositide signaling, which controls cell growth, survival, and metabolism.
• Essential for endocytic membrane trafficking and cargo sorting.
• Modulates immune cell activation at the immunological synapse.
• Involved in host-pathogen interactions; bacterial phosphatases can inhibit pyroptosis.
• Mutations in INPPL1 cause opsismodysplasia, a skeletal dysplasia.
• Altered expression of lipid phosphate phosphatases is linked to cancer progression.
• Provides targets for drug development, e.g., SHIP2 inhibitors.
• Serves as a paradigm for studying lipid-mediated signal transduction.
• Can be studied with CRISPR screens to identify novel phosphatases and their functions.
• Contributes to the regulation of nuclear AKT activation via a p53-phosphoinositide signalosome.
What Happens During phospholipid dephosphorylation?
Substrate recognition and binding
In simple terms: The enzyme finds and grabs the lipid that needs its phosphate removed.
Lipid phosphatases such as LPPs and SHIP2 recognize specific phosphorylated lipids within membrane bilayers. For instance, SHIP2 binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3) through its SH2 domain and other regulatory interactions, positioning its catalytic domain for dephosphorylation. LPPs, on the other hand, act on phosphatidic acid and other lipid phosphates, and their substrate specificity is determined by membrane composition and enzyme localization. This step ensures that only the correct lipid substrate is targeted at the right time and place.
Catalytic hydrolysis of the phosphate ester
In simple terms: The enzyme cuts the phosphate group off the lipid using water.
The catalytic mechanism involves a nucleophilic attack by a water molecule on the phosphorus atom of the phosphate ester, often assisted by a divalent metal ion or an aspartate residue in the active site. This hydrolysis releases inorganic phosphate and the dephosphorylated lipid product. For SHIP2, the reaction converts PIP3 to phosphatidylinositol (3,4)-bisphosphate, thereby terminating PI3K-dependent signaling. The reaction is highly regulated and can be influenced by the lipid environment and post-translational modifications of the enzyme.
Product release and membrane remodeling
In simple terms: The changed lipid stays in the membrane and alters its properties.
After dephosphorylation, the product lipid often has altered charge and affinity for effector proteins, leading to changes in membrane identity and protein recruitment. For example, the conversion of PIP3 to PI(3,4)P2 by SHIP2 affects the recruitment of pleckstrin homology (PH) domain-containing proteins, thereby modulating downstream signaling. In endocytosis, dephosphorylation of phosphoinositides is required for vesicle scission and uncoating, highlighting the role of this process in membrane remodeling.
Integration with cellular signaling networks
In simple terms: The removal of phosphate sends signals that change cell behavior.
Phospholipid dephosphorylation is not an isolated event; it is integrated with kinase signaling, GTPase cycles, and protein-protein interactions. For instance, the p53-phosphoinositide signalosome regulates nuclear AKT activation through phosphoinositide dephosphorylation, linking this process to DNA damage responses and cell survival. In the immunological synapse, lipid switches involving dephosphorylation control T-cell receptor signaling and immune activation. Thus, this process serves as a critical node in cellular decision-making.
Key Genes Involved in GO:0046839 phospholipid dephosphorylation
The following genes encode enzymes and regulators that directly participate in or modulate phospholipid dephosphorylation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| INPPL1 (SHIP2) | 5-phosphatase that dephosphorylates PIP3 to PI(3,4)P2 | Mutations cause opsismodysplasia; target for cancer and diabetes research |
| PPAP2A (LPP1) | Lipid phosphate phosphatase acting on phosphatidic acid and other lipids | Regulates cell proliferation and migration; implicated in cancer |
| PPAP2B (LPP3) | Lipid phosphate phosphatase with roles in development and angiogenesis | Loss linked to vascular defects and cancer |
| PPAP2C (LPP2) | Lipid phosphate phosphatase involved in sphingolipid metabolism | Potential tumor suppressor; studied in cancer models |
| PTEN | Dephosphorylates PIP3 to PIP2 | Classic tumor suppressor; frequently mutated in cancers |
| INPP4A | Inositol polyphosphate 4-phosphatase | Regulates endosomal trafficking and signaling |
| INPP4B | Inositol polyphosphate 4-phosphatase type II | Tumor suppressor in breast and other cancers |
| INPP5D (SHIP1) | 5-phosphatase in hematopoietic cells | Regulates immune cell signaling and inflammation |
| SAC1 (SACM1L) | Phosphatidylinositol 4-phosphatase | Controls Golgi phosphoinositide homeostasis |
| FIG4 | Polyphosphatidylinositol 5-phosphatase | Mutations cause Charcot-Marie-Tooth disease and Yunis-Varon syndrome |
| MTM1 | Myotubularin, 3-phosphatase | Mutations cause X-linked myotubular myopathy |
| MTMR2 | Myotubularin-related 2, 3-phosphatase | Mutations cause Charcot-Marie-Tooth disease type 4B1 |
| TPTE2 | Phosphatidylinositol 3-phosphatase | Regulates PIP3 levels and cell migration |
| PLPP1 | Lipid phosphate phosphatase 1 | Modulates lysophospholipid signaling |
| PLPP3 | Lipid phosphate phosphatase 3 | Involved in angiogenesis and atherosclerosis |
| PTPMT1 | Protein tyrosine phosphatase, mitochondrial 1 | Dephosphorylates phosphatidylglycerol and cardiolipin |
| CDC25 | Phosphatase involved in cell cycle regulation | Can act on lipid substrates in some contexts |
| PTPN11 (SHP2) | Protein tyrosine phosphatase with lipid phosphatase activity | Mutations cause Noonan syndrome and leukemia |
How Is phospholipid dephosphorylation Regulated?
Phospholipid dephosphorylation is regulated at multiple levels, including enzyme localization, post-translational modifications, and interaction with regulatory proteins. For example, SHIP2 activity is controlled by its SH2 domain, which binds phosphotyrosine motifs on activated receptors, and by phosphorylation that modulates its catalytic activity. The p53-phosphoinositide signalosome regulates nuclear AKT activation by coordinating phosphoinositide dephosphorylation, linking this process to DNA damage responses. In the immunological synapse, lipid switches involving dephosphorylation are dynamically regulated to fine-tune T-cell activation. Additionally, bacterial pathogens can secrete phosphatases that hijack host ubiquitin to inhibit pyroptosis, illustrating pathogen-driven regulation of this process. These layers of regulation ensure that phospholipid dephosphorylation occurs at the right time and place to maintain cellular homeostasis.
phospholipid dephosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| INPPL1 | Opsismodysplasia | Knockout or point-mutation knock-in in chondrocyte cell lines or mouse models |
| PTEN | Cancer (multiple types) | Knockout in cancer cell lines; overexpression of wild-type vs. mutant |
| MTM1 | X-linked myotubular myopathy | Knockout in muscle cells; knock-in of patient mutations |
| MTMR2 | Charcot-Marie-Tooth disease type 4B1 | Knockout in Schwann cells; point-mutation knock-in |
| FIG4 | Charcot-Marie-Tooth disease, Yunis-Varon syndrome | Knockout in neuronal cells; overexpression of mutant |
Cancer
Dysregulation of phospholipid dephosphorylation is frequently observed in cancer. Loss of PTEN, a lipid phosphatase that dephosphorylates PIP3, leads to hyperactivation of PI3K/AKT signaling and is a hallmark of many cancers. Similarly, reduced expression of lipid phosphate phosphatases (LPPs) such as PPAP2A and PPAP2B has been associated with tumor progression and poor prognosis. SHIP2 (INPPL1) is also implicated in cancer; its inhibition is being explored as a therapeutic strategy. These findings underscore the importance of lipid phosphatases as tumor suppressors and drug targets.
Opsismodysplasia
Mutations in INPPL1, which encodes SHIP2, cause opsismodysplasia, a rare skeletal dysplasia characterized by delayed bone mineralization and short stature. These mutations often result in loss of SHIP2 phosphatase activity, leading to altered phosphoinositide signaling in chondrocytes. This disease highlights the critical role of phospholipid dephosphorylation in skeletal development and provides a model for studying the function of SHIP2 in vivo.
Immune disorders and infection
Phospholipid dephosphorylation is essential for immune cell function. In the immunological synapse, lipid switches involving dephosphorylation regulate T-cell activation and tolerance. Pathogens can exploit this process: a bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin, thereby evading immune clearance. These examples illustrate how perturbations in phospholipid dephosphorylation can lead to immune dysregulation and increased susceptibility to infection.
Neurological disorders
Mutations in lipid phosphatases such as MTM1 and MTMR2 cause X-linked myotubular myopathy and Charcot-Marie-Tooth disease type 4B1, respectively. These disorders are characterized by defects in membrane trafficking and myelination, highlighting the importance of phospholipid dephosphorylation in neuronal and muscle function. Although the exact mechanisms are still being elucidated, these diseases underscore the non-redundant roles of specific lipid phosphatases in human physiology.
From phospholipid dephosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of INPPL1 affect phosphoinositide levels and bone development? | INPPL1 knockout cell line (e.g., chondrocytes) and knock-in of patient mutations |
| What is the role of SHIP2 catalytic activity in cancer cell proliferation? | Point mutation (catalytic dead) knock-in in cancer cell lines |
| How does PTEN dephosphorylation of PIP3 regulate AKT signaling? | PTEN knockout and overexpression of wild-type vs. phosphatase-dead mutant |
| Does LPP3 dephosphorylation of phosphatidic acid control angiogenesis? | Endothelial cell knockout and overexpression models |
| Can bacterial phosphatase inhibit pyroptosis in host cells? | Overexpression of bacterial phosphatase in macrophages; knockout of host ubiquitin components |
| What is the impact of INPP4A on endosomal trafficking? | Knockout and tagged knock-in for live-cell imaging |
How to Study the phospholipid dephosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Quantification of lipid species and phosphorylation states | Profiling changes in phosphoinositides upon phosphatase knockout |
| Fluorescence biosensors | Real-time dynamics of specific phosphoinositides | Visualizing PIP3 dephosphorylation by SHIP2 in live cells |
| In vitro phosphatase assay | Enzymatic activity of lipid phosphatases | Characterizing mutant enzymes and testing inhibitors |
| CRISPR knockout screens | Genes required for cell fitness in context of phosphatase loss | Identifying synthetic lethal interactions in cancer |
| Immunoblotting | Protein expression and phosphorylation status | Validating knockout efficiency and downstream signaling |
| Co-immunoprecipitation | Protein-protein interactions | Identifying regulators of lipid phosphatases |
| Live-cell imaging | Subcellular localization and trafficking | Tracking endocytosis and membrane remodeling |
| RNA-seq | Transcriptional changes | Assessing global gene expression upon phosphatase perturbation |
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics allows comprehensive profiling of phospholipid species and their phosphorylation states. By comparing wild-type and knockout cells, researchers can quantify changes in phosphatidic acid, phosphoinositides, and other lipids, thereby directly measuring the impact of phospholipid dephosphorylation. This method is essential for validating enzyme-substrate relationships and for discovering novel lipid substrates.
Fluorescence imaging and biosensors
Genetically encoded biosensors, such as GFP-tagged PH domains that bind specific phosphoinositides, enable real-time visualization of lipid dephosphorylation in live cells. For example, the translocation of AKT-PH domain biosensors can report PIP3 levels and SHIP2 activity. Advanced microscopy techniques, including TIRF and confocal imaging, allow researchers to track lipid dynamics at the plasma membrane and endosomes.
Phosphatase activity assays
In vitro phosphatase assays using radiolabeled or fluorescent lipid substrates provide direct measurements of enzymatic activity. These assays can be performed with recombinant enzymes or immunoprecipitated proteins from cell lysates. They are particularly useful for characterizing mutant enzymes, such as those found in opsismodysplasia, and for screening inhibitors like SHIP2 inhibitors.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that regulate phospholipid dephosphorylation or that are synthetically lethal with phosphatase loss. Such screens have the power to uncover novel components of lipid signaling networks and to pinpoint vulnerabilities in cancer cells with altered lipid phosphatase expression. Combined with bioinformatics, these approaches accelerate target discovery.
How CRISPR Can Be Used to Study GO:0046839 phospholipid dephosphorylation
Knockout
CRISPR knockout of lipid phosphatase genes such as INPPL1, PTEN, or PPAP2A allows researchers to study the loss-of-function phenotypes in relevant cell types. For example, INPPL1 knockout in chondrocytes can model opsismodysplasia and reveal downstream signaling defects. Knockout of PTEN in cancer cell lines leads to constitutive AKT activation, providing a system to test PI3K inhibitors. These models are essential for establishing causal roles of specific phosphatases in cellular processes and disease.
Point Mutation
Point mutations that abolish catalytic activity (e.g., in the phosphatase domain of SHIP2 or PTEN) can be introduced via CRISPR to distinguish enzymatic from scaffolding functions. Such knock-in models are particularly valuable for studying disease-associated mutations, such as those found in opsismodysplasia, where the phosphatase activity of SHIP2 is impaired. By comparing catalytic-dead mutants with complete knockouts, researchers can dissect the contribution of the enzymatic activity to the phenotype.
Knock-in
Knock-in of tagged versions of lipid phosphatases (e.g., GFP or HA tags) enables live-cell imaging and proteomic analysis of the endogenous proteins. This approach preserves native regulation and expression levels, providing more physiologically relevant insights than overexpression. For example, a GFP knock-in of INPP4A can be used to track its localization to endosomes and its role in trafficking. Knock-in of patient-specific mutations also allows modeling of genetic diseases in isogenic cell lines.
Overexpression
Overexpression of wild-type or mutant lipid phosphatases is a powerful gain-of-function approach to study their effects on lipid signaling and cell behavior. For instance, overexpression of SHIP2 reduces PIP3 levels and inhibits AKT activation, mimicking the effect of PTEN. Overexpression of bacterial phosphatases in host cells can suppress pyroptosis, as shown for a bacterial phospholipid phosphatase that hijacks ubiquitin. These models are useful for screening inhibitors and for validating drug targets.
How EDITGENE Supports phospholipid dephosphorylation Research
Researchers studying phospholipid dephosphorylation-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies of lipid phosphatases and their regulators.
Contact EDITGENE today to design your custom CRISPR model for phospholipid dephosphorylation research.
Frequently Asked Questions About phospholipid dephosphorylation
What is phospholipid dephosphorylation?
Phospholipid dephosphorylation (GO:0046839) is the biological process of removing one or more phosphate groups from a phosphorylated lipid, thereby regulating lipid signaling and membrane dynamics.
What genes are involved in phospholipid dephosphorylation?
Key genes include INPPL1 (SHIP2), PTEN, PPAP2A/B/C (LPPs), INPP4A/B, MTM1, MTMR2, FIG4, and others encoding lipid phosphatases.
What is the role of SHIP2 in phospholipid dephosphorylation?
SHIP2 (encoded by INPPL1) is a 5-phosphatase that dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate to PI(3,4)-bisphosphate, thereby terminating PI3K signaling.
How is phospholipid dephosphorylation linked to cancer?
Loss of lipid phosphatases such as PTEN and LPPs leads to accumulation of phosphorylated lipids that drive proliferation and survival, contributing to cancer development.
What diseases are associated with mutations in phospholipid phosphatases?
Mutations in INPPL1 cause opsismodysplasia; MTM1 mutations cause X-linked myotubular myopathy; MTMR2 and FIG4 mutations cause Charcot-Marie-Tooth disease.
How can CRISPR be used to study phospholipid dephosphorylation?
CRISPR knockout, point mutation, and knock-in models allow researchers to disrupt or modify specific lipid phosphatase genes and study the resulting changes in lipid signaling and cell behavior.
What methods are used to measure phospholipid dephosphorylation?
Common methods include lipidomics, fluorescence biosensors, in vitro phosphatase assays, and CRISPR screens.
What is the substrate of lipid phosphate phosphatases?
Lipid phosphate phosphatases (LPPs) act on phosphatidic acid and other phosphorylated lipids, removing phosphate groups to generate diacylglycerol or other products.
How does phospholipid dephosphorylation affect the immune system?
It regulates phosphoinositide signaling at the immunological synapse and can be hijacked by bacterial pathogens to inhibit pyroptosis.
Why is phospholipid dephosphorylation important for cell signaling?
By reversing lipid kinase action, it controls the levels of second messengers like PIP3, thereby shaping downstream signaling pathways such as AKT.
Conclusion
Phospholipid dephosphorylation (GO:0046839) is a cornerstone of lipid signaling that impacts diverse cellular processes, from membrane trafficking to immune activation and cell survival. The growing list of lipid phosphatases and their links to human diseases such as cancer, opsismodysplasia, and neuropathies underscores the importance of this process in health and disease. Advances in CRISPR-based models and lipidomics are poised to accelerate the discovery of new therapeutic targets and deepen our understanding of how lipid phosphate signals are decoded.
References
- 1. Chai Q et al.. 2022. A bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin.. Science 378(6616):eabq0132 PMID: 36227980
- 2. Chen M et al.. 2022. A p53-phosphoinositide signalosome regulates nuclear AKT activation.. Nat Cell Biol 24(7):1099-1113 PMID: 35798843
- 3. Horn R. 2005. Electrifying phosphatases.. Sci STKE 2005(307):pe50 PMID: 16249403
- 4. Posor Y et al.. 2015. Phosphoinositides in endocytosis.. Biochim Biophys Acta 1851(6):794-804 PMID: 25264171
- 5. Tang X et al.. 2020. Lipid Phosphate Phosphatases and Cancer.. Biomolecules 10(9) PMID: 32887262
- 6. Thomas MP et al.. 2017. SHIP2: Structure, Function and Inhibition.. Chembiochem 18(3):233-247 PMID: 27907247
- 7. Griffiths G et al.. 2024. Lipid switches in the immunological synapse.. J Biol Chem 300(7):107428 PMID: 38823638
- 8. Fradet A et al.. 2017. INPPL1 gene mutations in opsismodysplasia.. J Hum Genet 62(2):135-140 PMID: 27708270
